NASDAQ:TRPX - THERAPIX BIOSCI/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.55 -0.22 (-5.84 %) (As of 01/16/2019 01:07 PM ET)Previous Close$3.77Today's Range$3.55 - $3.5952-Week Range$3.00 - $9.30Volume200 shsAverage Volume67,926 shsMarket Capitalization$13.46 millionP/E Ratio6.75Dividend YieldN/ABeta0.47 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110 for the treatment of Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for the treatment of Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. Therapix Biosciences Ltd. has a product development agreement with Cure Pharmaceutical to develop cannabinoid-based product for sleep disorders. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel. Receive TRPX News and Ratings via Email Sign-up to receive the latest news and ratings for TRPX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TRPX Previous Symbol CUSIPN/A Webwww.therapixbio.com Phone972-3616-7055Debt Debt-to-Equity RatioN/A Current Ratio3.42 Quick Ratio3.42Price-To-Earnings Trailing P/E Ratio6.75 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$1.6667 per share Price / Cash Flow2.13 Book Value$2.42 per share Price / Book1.47Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-6,240,000.00 Net MarginsN/A Return on Equity30.59% Return on Assets24.89%Miscellaneous Employees12 Outstanding Shares3,500,000Market Cap$13.46 million OptionableNot Optionable THERAPIX BIOSCI/S (NASDAQ:TRPX) Frequently Asked Questions What is THERAPIX BIOSCI/S's stock symbol? THERAPIX BIOSCI/S trades on the NASDAQ under the ticker symbol "TRPX." How were THERAPIX BIOSCI/S's earnings last quarter? THERAPIX BIOSCI/S (NASDAQ:TRPX) released its quarterly earnings data on Monday, December, 3rd. The company reported ($0.50) EPS for the quarter. View THERAPIX BIOSCI/S's Earnings History. When is THERAPIX BIOSCI/S's next earnings date? THERAPIX BIOSCI/S is scheduled to release their next quarterly earnings announcement on Monday, April 29th 2019. View Earnings Estimates for THERAPIX BIOSCI/S. Has THERAPIX BIOSCI/S been receiving favorable news coverage? News stories about TRPX stock have been trending positive on Wednesday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. THERAPIX BIOSCI/S earned a news impact score of 2.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an impact on the stock's share price in the near term. Who are some of THERAPIX BIOSCI/S's key competitors? Some companies that are related to THERAPIX BIOSCI/S include Arcturus Therapeutics (ARCT), Vistagen Therapeutics (VTGN), Selecta Biosciences (SELB), Synergy Pharmaceuticals (SGYP), Forward Pharma A/S (FWP), Evoke Pharma (EVOK), IntelGenx Technologies (IGXT), Nemus Bioscience (NMUS), Adial Pharmaceuticals (ADIL), ContraFect (CFRX), VIVUS (VVUS), Vaccinex (VCNX), Trevena (TRVN), DiaMedica Therapeutics (DMCAF) and OncoSec Medical (ONCS). Who are THERAPIX BIOSCI/S's key executives? THERAPIX BIOSCI/S's management team includes the folowing people: Dr. Ascher Shmulewitz, Chairman & Interim CEO (Age 63)Dr. Adi Zuloff-Shani, Chief Technology Officer (Age 51)Mr. Oz Adler CPA, Chief Financial Officer (Age 33) How do I buy shares of THERAPIX BIOSCI/S? Shares of TRPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is THERAPIX BIOSCI/S's stock price today? One share of TRPX stock can currently be purchased for approximately $3.55. How big of a company is THERAPIX BIOSCI/S? THERAPIX BIOSCI/S has a market capitalization of $13.46 million. THERAPIX BIOSCI/S employs 12 workers across the globe. What is THERAPIX BIOSCI/S's official website? The official website for THERAPIX BIOSCI/S is http://www.therapixbio.com. How can I contact THERAPIX BIOSCI/S? THERAPIX BIOSCI/S's mailing address is 4 Ariel Sharon StreetHaShahar Tower 16th Floor, Givatayim L3, 5320047. The company can be reached via phone at 972-3616-7055. MarketBeat Community Rating for THERAPIX BIOSCI/S (NASDAQ TRPX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 180 (Vote Outperform)Underperform Votes: 174 (Vote Underperform)Total Votes: 354MarketBeat's community ratings are surveys of what our community members think about THERAPIX BIOSCI/S and other stocks. Vote "Outperform" if you believe TRPX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRPX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/16/2019 by MarketBeat.com StaffFeatured Article: What is a Fiduciary?